Pharmacy and Poisons Board: Applications

Protocol No.	Study Title	Principal Investigator(s)	Name of Site / County	Pages	Clear
Application Submission Dates-to- clear!		Estimated Duration (Months)

#	Protocol No	Study Title	Investigator(s) & Site(s)	Date Approved
21.	ECCT/24/10/02	user abstract 123	Principal Investigator(s) 1. Irene Peterson Melinda Farrell Marah Bush Site(s) in Kenya 1. Harriet Battle (Kirinyaga county)	19-11-2024	View
22.	ECCT/25/01/09 - A	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Miranda Alvarez (Kisumu county)	13-01-2025	View
23.	ECCT/25/01/09 - B	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	13-01-2025	View
24.	ECCT/25/01/09 - DLoop	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	13-01-2025	View
25.	ECCT/25/01/09- KPCTYn	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	13-01-2025	View
26.	ECCT/24/05/03	\"Exploring Albenimol "Exploring the Therapeutic Potential of Albenimol: A Review of Its Antiparasitic and Anticancer Properties"	Principal Investigator(s) 1. Grace Omondi Site(s) in Kenya 1. Mombasa General Hospital (Mombasa county) 2. Kisumu Medical Center (Kisumu county) 3. Nakuru Community Hospital (Nakuru county) 4. Eldoret Health Center (Uasin Gishu county) 5. Thika District Hospital (Kiambu county) 6. Kitale Medical Clinic (Trans Nzoia county) 7. Machakos General Hospital (Machakos county)	21-06-2024	View

History
+
Request History
4 previous requests available
====
Session
+
Session
- Config(array)
  userAgent9c3d2c89526db53b7b69e8c9faa06145
  time1790949817
  countdown10
====
Request
+
Request

Cake Params
- plugin(null)
- controllerapplications
- actionindex
- named(array)
  sortstudy_title
  directiondesc
  statusapproved
  page3
- pass(empty)
- isAjax(false)
- paging(array)
  Application(array)
  page3
  current6
  count26
  prevPage(true)
  nextPage(false)
  pageCount3
  order(array)
  Application.study_titledesc
  limit10
  options(array)
  page3
  order(array)
  Application.study_titledesc
  sortstudy_title
  directiondesc
  paramTypenamed
Post data
- Application(array)
  statusapproved
Query string

No querystring data.

Cookie

To view Cookies, add CookieComponent to Controller

Current Route
- keys(array)
  0controller
  1action
- options(empty)
- defaults(array)
  plugin(null)
- template/:controller/:action/*
====

Sql Logs

default

Total Time: 9 ms
Total Queries: 20 queries

Query	Affected	Num. rows	Took (ms)	Actions
SELECT `Application`.`id`, `Application`.`user_id`, `Application`.`application_id`, `Application`.`is_child`, `Application`.`trial_status_id`, `Application`.`trial_status_date`, `Application`.`total_sites`, `Application`.`abstract_of_study`, `Application`.`study_title`, `Application`.`laymans_summary`, `Application`.`short_title`, `Application`.`protocol_no`, `Application`.`reference_no`, `Application`.`version_no`, `Application`.`date_of_protocol`, `Application`.`study_drug`, `Application`.`disease_condition`, `Application`.`product_type_biologicals`, `Application`.`product_type_proteins`, `Application`.`product_type_immunologicals`, `Application`.`product_type_vaccines`, `Application`.`product_type_hormones`, `Application`.`product_type_toxoid`, `Application`.`product_type_chemical`, `Application`.`product_type_medical_device`, `Application`.`product_type_chemical_name`, `Application`.`product_type_medical_device_name`, `Application`.`comparator`, `Application`.`comparator_name`, `Application`.`comparator_registered`, `Application`.`comparator_countries`, `Application`.`ecct_not_applicable`, `Application`.`ecct_ref_number`, `Application`.`email_address`, `Application`.`applicant_covering_letter`, `Application`.`applicant_protocol`, `Application`.`applicant_patient_information`, `Application`.`applicant_investigators_brochure`, `Application`.`applicant_investigators_cv`, `Application`.`applicant_signed_declaration`, `Application`.`applicant_financial_declaration`, `Application`.`applicant_gmp_certificate`, `Application`.`applicant_indemnity_cover`, `Application`.`applicant_opinion_letter`, `Application`.`applicant_approval_letter`, `Application`.`applicant_statement`, `Application`.`applicant_participating_countries`, `Application`.`applicant_addendum`, `Application`.`applicant_fees`, `Application`.`applicant_complete_form`, `Application`.`applicant_impd`, `Application`.`applicant_prev_data`, `Application`.`applicant_stability_data`, `Application`.`applicant_analysis_cert`, `Application`.`applicant_pictorial_sample`, `Application`.`applicant_gcp_training`, `Application`.`applicant_dsmb_charter`, `Application`.`applicant_detailed_budget`, `Application`.`applicant_indemnity_pi`, `Application`.`applicant_practice_license`, `Application`.`applicant_registration_ctr`, `Application`.`applicant_pan_african`, `Application`.`applicant_hard_copies`, `Application`.`applicant_signed_checklist`, `Application`.`statistical_analysis_plan`, `Application`.`applicant_contractual_agreement`, `Application`.`declaration_applicant`, `Application`.`declaration_date1`, `Application`.`declaration_principal_investigator`, `Application`.`declaration_date2`, `Application`.`protocol_not_ai_generated`, `Application`.`placebo_present`, `Application`.`study_objectives`, `Application`.`principal_inclusion_criteria`, `Application`.`principal_exclusion_criteria`, `Application`.`primary_end_points`, `Application`.`scope_diagnosis`, `Application`.`scope_prophylaxis`, `Application`.`scope_therapy`, `Application`.`scope_safety`, `Application`.`scope_efficacy`, `Application`.`scope_pharmacokinetic`, `Application`.`scope_pharmacodynamic`, `Application`.`scope_bioequivalence`, `Application`.`scope_dose_response`, `Application`.`scope_pharmacogenetic`, `Application`.`scope_pharmacogenomic`, `Application`.`scope_pharmacoecomomic`, `Application`.`scope_others`, `Application`.`scope_others_specify`, `Application`.`trial_human_pharmacology`, `Application`.`trial_administration_humans`, `Application`.`trial_bioequivalence_study`, `Application`.`trial_other`, `Application`.`trial_other_specify`, `Application`.`trial_therapeutic_exploratory`, `Application`.`trial_therapeutic_confirmatory`, `Application`.`trial_therapeutic_use`, `Application`.`design_controlled`, `Application`.`site_capacity`, `Application`.`staff_numbers`, `Application`.`other_details_explanation`, `Application`.`other_details_regulatory_notapproved`, `Application`.`other_details_regulatory_approved`, `Application`.`other_details_regulatory_rejected`, `Application`.`other_details_regulatory_halted`, `Application`.`estimated_duration`, `Application`.`design_controlled_randomised`, `Application`.`design_controlled_open`, `Application`.`design_controlled_single_blind`, `Application`.`design_controlled_double_blind`, `Application`.`design_controlled_parallel_group`, `Application`.`design_controlled_cross_over`, `Application`.`design_controlled_other`, `Application`.`design_controlled_specify`, `Application`.`design_controlled_comparator`, `Application`.`design_controlled_other_medicinal`, `Application`.`design_controlled_placebo`, `Application`.`design_controlled_medicinal_other`, `Application`.`design_controlled_medicinal_specify`, `Application`.`single_site_member_state`, `Application`.`location_of_area`, `Application`.`single_site_physical_address`, `Application`.`single_site_contact_person`, `Application`.`single_site_telephone`, `Application`.`multiple_sites_member_state`, `Application`.`multiple_countries`, `Application`.`multiple_member_states`, `Application`.`number_of_sites`, `Application`.`multi_country_list`, `Application`.`data_monitoring_committee`, `Application`.`total_enrolment_per_site`, `Application`.`total_participants_worldwide`, `Application`.`population_less_than_18_years`, `Application`.`population_utero`, `Application`.`population_preterm_newborn`, `Application`.`population_newborn`, `Application`.`population_infant_and_toddler`, `Application`.`population_children`, `Application`.`population_adolescent`, `Application`.`population_above_18`, `Application`.`population_adult`, `Application`.`population_elderly`, `Application`.`gender_female`, `Application`.`gender_male`, `Application`.`subjects_healthy`, `Application`.`subjects_patients`, `Application`.`subjects_vulnerable_populations`, `Application`.`subjects_women_child_bearing`, `Application`.`subjects_women_using_contraception`, `Application`.`subjects_pregnant_women`, `Application`.`subjects_nursing_women`, `Application`.`subjects_emergency_situation`, `Application`.`subjects_incapable_consent`, `Application`.`subjects_specify`, `Application`.`subjects_others`, `Application`.`subjects_others_specify`, `Application`.`investigator1_given_name`, `Application`.`investigator1_middle_name`, `Application`.`investigator1_family_name`, `Application`.`investigator1_qualification`, `Application`.`investigator1_professional_address`, `Application`.`investigator1_telephone`, `Application`.`investigator1_email`, `Application`.`organisations_transferred_`, `Application`.`number_participants`, `Application`.`notification`, `Application`.`approval_date`, `Application`.`submitted`, `Application`.`deleted`, `Application`.`deleted_date`, `Application`.`deactivated`, `Application`.`date_submitted`, `Application`.`unsubmitted`, `Application`.`initial_date_submitted`, `Application`.`admin_stopped`, `Application`.`admin_stopped_reason`, `Application`.`approved`, `Application`.`approved_reason`, `Application`.`approved_date`, `Application`.`final_report`, `Application`.`implication_results`, `Application`.`quantity_imported`, `Application`.`quantity_dispensed`, `Application`.`quantity_destroyed`, `Application`.`quantity_exported`, `Application`.`balance_site`, `Application`.`final_date`, `Application`.`ecitizen_invoice`, `Application`.`modified`, `Application`.`created`, `Application`.`ai_content` FROM `ctr`.`applications` AS `Application` WHERE `Application`.`approved` = 2 AND `Application`.`deactivated` = '0' AND `Application`.`submitted` = '1' AND `Application`.`deleted` = '0' ORDER BY `Application`.`study_title` desc LIMIT 20, 10	6	6	7	maybe slow
SELECT `InvestigatorContact`.`id`, `InvestigatorContact`.`application_id`, `InvestigatorContact`.`given_name`, `InvestigatorContact`.`middle_name`, `InvestigatorContact`.`family_name`, `InvestigatorContact`.`qualification`, `InvestigatorContact`.`professional_address`, `InvestigatorContact`.`telephone`, `InvestigatorContact`.`email`, `InvestigatorContact`.`investigator_role`, `InvestigatorContact`.`created`, `InvestigatorContact`.`modified` FROM `ctr`.`investigator_contacts` AS `InvestigatorContact` WHERE `InvestigatorContact`.`application_id` IN (120, 158, 159, 160, 118, 43)	6	6	0
SELECT `SiteDetail`.`id`, `SiteDetail`.`application_id`, `SiteDetail`.`county_id`, `SiteDetail`.`site_name`, `SiteDetail`.`physical_address`, `SiteDetail`.`contact_details`, `SiteDetail`.`contact_person`, `SiteDetail`.`site_capacity`, `SiteDetail`.`misc`, `SiteDetail`.`created`, `SiteDetail`.`modified` FROM `ctr`.`site_details` AS `SiteDetail` WHERE `SiteDetail`.`application_id` IN (120, 158, 159, 160, 118, 43)	12	12	2	maybe slow
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 1	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 42	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 42	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 32	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 27	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 22	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 26	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 16	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 20	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `Sponsor`.`id`, `Sponsor`.`application_id`, `Sponsor`.`sponsor`, `Sponsor`.`sponsor_type`, `Sponsor`.`contact_person`, `Sponsor`.`address`, `Sponsor`.`telephone_number`, `Sponsor`.`fax_number`, `Sponsor`.`cell_number`, `Sponsor`.`email_address`, `Sponsor`.`created`, `Sponsor`.`modified` FROM `ctr`.`sponsors` AS `Sponsor` WHERE `Sponsor`.`application_id` IN (120, 158, 159, 160, 118, 43)	6	6	0
SELECT COUNT(*) AS `count` FROM `ctr`.`applications` AS `Application` WHERE `Application`.`approved` = 2 AND `Application`.`deactivated` = '0' AND `Application`.`submitted` = '1' AND `Application`.`deleted` = '0'	1	1	0
SELECT `TrialStatus`.`id` FROM `ctr`.`trial_statuses` AS `TrialStatus` WHERE `TrialStatus`.`name` = 'Suspended' LIMIT 1	1	1	0
SELECT `TrialStatus`.`id` FROM `ctr`.`trial_statuses` AS `TrialStatus` WHERE `TrialStatus`.`name` = 'Stopped' LIMIT 1	1	1	0
SELECT `TrialStatus`.`id`, `TrialStatus`.`name` FROM `ctr`.`trial_statuses` AS `TrialStatus` WHERE 1 = 1	12	12	0

3 duplicate queries run.

Query Explain:

Click an "Explain" link above, to see the query explanation.

====

Timer

Memory

Peak Memory Use 12.67 MB

Message	Memory use
Component initialization	2.43 MB
Controller action start	3.63 MB
Controller render start	4.79 MB
View render complete	5.29 MB

Timers

Total Request Time: 108 (ms)

Message	Time in ms	Graph
Core Processing (Derived from $_SERVER["REQUEST_TIME"])	10.52
Event: Controller.initialize	0.26
Event: Controller.startup	0.67
Controller action	30.73
Event: Controller.beforeRender	23.00
» Processing toolbar data	22.87
Rendering View	11.07
» Event: View.beforeRender	0.03
» Rendering APP/View/Applications/index.ctp	0.20
» » Rendering APP/View/Elements/google-recommend.ctp	0.05
» Rendering APP/View/Elements/application/public_index.ctp	7.34
» Event: View.afterRender	0.02
» Event: View.beforeLayout	0.02
» Rendering APP/View/Layouts/default.ctp	3.08
» » Rendering APP/View/Elements/google-analytics.ctp	0.05
Event: View.afterLayout	0.00

====

Log
+

Logs

There were no log entries made this request

====
Variables
+
View Variables
- trial_statuses(array)
  1Recruiting
  2Not yet recruiting
  3Suspended
  4Stopped
  5Completed
  6In follow-up
  7Analysing
  8Writing-up
  9Application withdrawn
  10Paused or preparation for extension of study
  11Revoked
  12Ongoing Closeout Phase
- action_date_fieldapproval_date
- statusapproved
- applications(array)
  0(array)
  Application(array)
  id120
  user_id82
  application_id(null)
  is_child0
  trial_status_id(null)
  trial_status_date(null)
  total_sites1
  abstract_of_study<p>\n studyabstract</p>\n
  study_title<p>\n abstract 123</p>\n
  laymans_summary<p>\n layman</p>\n
  short_titleuser
  protocol_noECCT/24/10/02
  reference_no(null)
  version_no2
  date_of_protocol09-10-2024
  study_drugstudydrug
  disease_conditionmalaria
  product_type_biologicals1
  product_type_proteins1
  product_type_immunologicals0
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorNo
  comparator_name
  comparator_registered
  comparator_countries
  ecct_not_applicable0
  ecct_ref_number
  email_addresslchepkwony@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicantDeleniti et autem ea omnis
  declaration_date104-05-2023
  declaration_principal_investigatorQuaerat aspernatur consequatur non voluptas inventore ad officiis do consequatur voluptates enim asperiores minim illum
  declaration_date218-01-2014
  protocol_not_ai_generated0
  placebo_presentYes
  study_objectives<p>\n objective</p>\n
  principal_inclusion_criteria<p>\n inclusion</p>\n
  principal_exclusion_criteria<p>\n exclusion</p>\n
  primary_end_points<p>\n end point</p>\n
  scope_diagnosis1
  scope_prophylaxis1
  scope_therapy0
  scope_safety1
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic0
  scope_bioequivalence1
  scope_dose_response0
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic1
  scope_others1
  scope_others_specifySit ut lorem ut vel
  trial_human_pharmacology1
  trial_administration_humans0
  trial_bioequivalence_study1
  trial_other0
  trial_other_specify
  trial_therapeutic_exploratory0
  trial_therapeutic_confirmatory0
  trial_therapeutic_use1
  design_controlledYes
  site_capacity(null)
  staff_numbers<p>\n 1234</p>\n
  other_details_explanation<p>\n explained</p>\n
  other_details_regulatory_notapproved<p>\n reg</p>\n
  other_details_regulatory_approved<p>\n reg</p>\n
  other_details_regulatory_rejected<p>\n reg</p>\n
  other_details_regulatory_halted
  estimated_durationEsse ducimus possimus aut architecto esse in dolor illum tempor cillum
  design_controlled_randomisedNo
  design_controlled_openNo
  design_controlled_single_blindNo
  design_controlled_double_blindNo
  design_controlled_parallel_groupNo
  design_controlled_cross_overNo
  design_controlled_otherYes
  design_controlled_specifyNeque deserunt nostrud minima aut sed enim veniam odit assumenda officia
  design_controlled_comparatorRepellendus Sed temporib
  design_controlled_other_medicinalYes
  design_controlled_placeboYes
  design_controlled_medicinal_otherNo
  design_controlled_medicinal_specify
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesYes
  multiple_member_states772
  number_of_sites961
  multi_country_listDelectus suscipit e
  data_monitoring_committeeNo
  total_enrolment_per_siteDolor sint animi er
  total_participants_worldwideCorrupti laudantium similique cupiditate nostrum rerum est vero laborum adipisicing
  population_less_than_18_yearsYes
  population_uteroNo
  population_preterm_newbornNo
  population_newbornYes
  population_infant_and_toddlerNo
  population_childrenNo
  population_adolescentYes
  population_above_18Yes
  population_adultYes
  population_elderlyNo
  gender_female1
  gender_male0
  subjects_healthyNo
  subjects_patientsNo
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingNo
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenNo
  subjects_nursing_womenYes
  subjects_emergency_situationYes
  subjects_incapable_consentYes
  subjects_specifyVoluptatum perspicia
  subjects_othersNo
  subjects_others_specify
  investigator1_given_nameBrent Mcknight
  investigator1_middle_nameNicole Gross
  investigator1_family_nameCharles Crane
  investigator1_qualificationId adipisci commodo repellendus Dolor enim iste et quam deserunt id ut ullamco
  investigator1_professional_addressQuia eius aut adipisicing rerum aut ad tempora necessitatibus cumque nisi at
  investigator1_telephone+1 (795) 542-5315
  investigator1_emaildudahabewy@mailinator.com
  organisations_transferred_No
  number_participantsVoluptatem ut nisi e
  notification
  approval_date19-11-2024
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted23-10-2024
  unsubmitted0
  initial_date_submitted(null)
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonApproved Here successfully
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice324112
  modified2024-11-19 16:25:21
  created2024-10-17 12:04:18
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id72
  application_id120
  given_nameIrene Peterson
  middle_nameMelinda Farrell
  family_nameMarah Bush
  qualificationId ipsa qui obcaecati sit iste eu reiciendis pariatur Possimus temporibus consequatur et culpa ad tenetur iusto inventore nihil labore
  professional_addressCorporis ut quo libero ut ullam error
  telephone+1 (524) 915-1935
  emailpypamyhezu@mailinator.com
  investigator_roleprincipal
  created2024-10-17 12:49:37
  modified2024-10-23 15:04:34
  SiteDetail(array)
  0(array)
  id1704
  application_id120
  county_id20
  site_nameHarriet Battle
  physical_addressQuae nulla sunt culpa beatae fugiat dolor quae labore similique in quae dignissimos a tempore ut tempore
  contact_detailsP.O. Box 5325
  contact_personNisi eum dolorem fugiat ullam dolore nemo laudantium aut autem natus similique numquam deserunt omnis quod officia
  site_capacity(null)
  misc(null)
  created2024-10-17 12:49:37
  modified2024-10-23 15:04:34
  County(array)
  id20
  county_nameKirinyaga
  created2012-06-15 10:24:22
  modified2012-06-15 10:24:22
  Sponsor(array)
  0(array)
  id29
  application_id120
  sponsorFuga Aut qui est consequatur consectetur dolorem qui blanditiis saepe natus maiores ea repellendus Velit quia ullamco
  sponsor_typeResearch Institution
  contact_personNon corrupti reiciendis placeat elit aut voluptatibus optio labore excepteur
  addressConsectetur ut ipsum quia quos magni
  telephone_number+1 (367) 517-6326
  fax_number+1 (961) 772-5694
  cell_number+1 (895) 885-1686
  email_addressrimumaxy@mailinator.com
  created2024-10-17 12:49:37
  modified2024-10-23 15:04:34
  PublicAction(array)
  labelApproved
  date19-11-2024
  1(array)
  Application(array)
  id158
  user_id86
  application_id118
  is_child1
  trial_status_id7
  trial_status_date(null)
  total_sites5
  abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
  study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
  short_titleVirunex-3 Trial for Novacov-24
  protocol_noECCT/25/01/09 - A
  reference_no1234redwsqa
  version_nov1
  date_of_protocol01-01-2025
  study_drugVirunex-3
  disease_conditionNovacov-24 Virus Infection
  product_type_biologicals1
  product_type_proteins0
  product_type_immunologicals1
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorNo
  comparator_name
  comparator_registered
  comparator_countries
  ecct_not_applicable0
  ecct_ref_number
  email_addressjkiprotich@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
  declaration_date110-01-2025
  declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
  declaration_date209-01-2025
  protocol_not_ai_generated0
  placebo_presentYes
  study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  scope_diagnosis1
  scope_prophylaxis0
  scope_therapy0
  scope_safety0
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic1
  scope_bioequivalence0
  scope_dose_response1
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic1
  scope_others1
  scope_others_specifyIn odit voluptate fu
  trial_human_pharmacology0
  trial_administration_humans1
  trial_bioequivalence_study0
  trial_other1
  trial_other_specifyVoluptas veniam ut
  trial_therapeutic_exploratory0
  trial_therapeutic_confirmatory1
  trial_therapeutic_use1
  design_controlledYes
  site_capacity(null)
  staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_rejected
  other_details_regulatory_halted
  estimated_durationTempore id architecto quaerat ad vel
  design_controlled_randomisedNo
  design_controlled_openYes
  design_controlled_single_blindNo
  design_controlled_double_blindYes
  design_controlled_parallel_groupNo
  design_controlled_cross_overYes
  design_controlled_otherYes
  design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
  design_controlled_comparatorAut qui perspiciatis rei
  design_controlled_other_medicinalNo
  design_controlled_placeboNo
  design_controlled_medicinal_otherYes
  design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesNo
  multiple_member_states
  number_of_sites6
  multi_country_list
  data_monitoring_committeeNo
  total_enrolment_per_siteVitae voluptatem se
  total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
  population_less_than_18_yearsYes
  population_uteroYes
  population_preterm_newbornYes
  population_newbornYes
  population_infant_and_toddlerNo
  population_childrenYes
  population_adolescentNo
  population_above_18Yes
  population_adultNo
  population_elderlyNo
  gender_female1
  gender_male0
  subjects_healthyNo
  subjects_patientsYes
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingNo
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenNo
  subjects_nursing_womenYes
  subjects_emergency_situationNo
  subjects_incapable_consentYes
  subjects_specifyId tempora omnis vol
  subjects_othersYes
  subjects_others_specifyUllam laborum Eos
  investigator1_given_nameIlliana Ferguson
  investigator1_middle_nameAllen Fox
  investigator1_family_nameYolanda Rivera
  investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
  investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
  investigator1_telephone+1 (621) 831-1153
  investigator1_emailqeryrilu@mailinator.com
  organisations_transferred_Yes
  number_participantsMinim dolor commodo
  notification
  approval_date13-01-2025
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted22-01-2025
  unsubmitted1
  initial_date_submitted22-01-2025
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonThis is approved
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice324073
  modified2025-02-13 08:07:31
  created2025-01-22 10:39:23
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id91
  application_id158
  given_nameHiroko Lewis
  middle_nameTatyana Medina
  family_nameCastor Gallagher
  qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
  professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
  telephone+1 (322) 766-3057
  emailtipyhuqo@mailinator.com
  investigator_roleprincipal
  created2025-01-13 12:13:08
  modified2025-02-13 08:07:31
  SiteDetail(array)
  0(array)
  id128
  application_id158
  county_id42
  site_nameMiranda Alvarez
  physical_addressAut ad quasi commodi non sint libero enim eos consequatur corrupti harum non
  contact_detailsP.O. Box 86856
  contact_personVoluptatibus molestias eligendi non repudiandae quis ipsa minim quia nostrum ut nisi possimus veniam
  site_capacity(null)
  misc(null)
  created2013-06-27 10:49:32
  modified2025-02-13 08:07:31
  County(array)
  id42
  county_nameKisumu
  created2012-06-15 10:27:02
  modified2012-06-15 10:27:02
  Sponsor(array)
  0(array)
  id39
  application_id158
  sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
  sponsor_typeLocal Kenyan Investigator
  contact_personDolorem mollitia id quis provident error voluptatem voluptate
  addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
  telephone_number+1 (666) 325-1183
  fax_number+1 (314) 248-5575
  cell_number+1 (134) 102-6236
  email_addresstuhokelyh@mailinator.com
  created2025-01-13 12:13:08
  modified2025-02-13 08:07:31
  PublicAction(array)
  labelApproved
  date13-01-2025
  2(array)
  Application(array)
  id159
  user_id86
  application_id118
  is_child1
  trial_status_id(null)
  trial_status_date(null)
  total_sites5
  abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
  study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
  short_titleVirunex-3 Trial for Novacov-24
  protocol_noECCT/25/01/09 - B
  reference_no1234redwsqa
  version_nov1
  date_of_protocol01-01-2025
  study_drugVirunex-3
  disease_conditionNovacov-24 Virus Infection
  product_type_biologicals1
  product_type_proteins0
  product_type_immunologicals1
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorNo
  comparator_name
  comparator_registered
  comparator_countries
  ecct_not_applicable0
  ecct_ref_number
  email_addressjkiprotich@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
  declaration_date110-01-2025
  declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
  declaration_date209-01-2025
  protocol_not_ai_generated0
  placebo_presentYes
  study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  scope_diagnosis1
  scope_prophylaxis0
  scope_therapy0
  scope_safety0
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic1
  scope_bioequivalence0
  scope_dose_response1
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic1
  scope_others1
  scope_others_specifyIn odit voluptate fu
  trial_human_pharmacology0
  trial_administration_humans1
  trial_bioequivalence_study0
  trial_other1
  trial_other_specifyVoluptas veniam ut
  trial_therapeutic_exploratory0
  trial_therapeutic_confirmatory1
  trial_therapeutic_use1
  design_controlledYes
  site_capacity(null)
  staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_rejected
  other_details_regulatory_halted
  estimated_durationTempore id architecto quaerat ad vel
  design_controlled_randomisedNo
  design_controlled_openYes
  design_controlled_single_blindNo
  design_controlled_double_blindYes
  design_controlled_parallel_groupNo
  design_controlled_cross_overYes
  design_controlled_otherYes
  design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
  design_controlled_comparatorAut qui perspiciatis rei
  design_controlled_other_medicinalNo
  design_controlled_placeboNo
  design_controlled_medicinal_otherYes
  design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesYes
  multiple_member_states668
  number_of_sites9
  multi_country_listAdipisicing et numqu
  data_monitoring_committeeYes
  total_enrolment_per_siteVitae voluptatem se
  total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
  population_less_than_18_yearsYes
  population_uteroYes
  population_preterm_newbornYes
  population_newbornYes
  population_infant_and_toddlerNo
  population_childrenYes
  population_adolescentNo
  population_above_18Yes
  population_adultNo
  population_elderlyNo
  gender_female1
  gender_male0
  subjects_healthyNo
  subjects_patientsYes
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingNo
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenNo
  subjects_nursing_womenYes
  subjects_emergency_situationNo
  subjects_incapable_consentYes
  subjects_specifyId tempora omnis vol
  subjects_othersYes
  subjects_others_specifyUllam laborum Eos
  investigator1_given_nameIlliana Ferguson
  investigator1_middle_nameAllen Fox
  investigator1_family_nameYolanda Rivera
  investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
  investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
  investigator1_telephone+1 (621) 831-1153
  investigator1_emailqeryrilu@mailinator.com
  organisations_transferred_Yes
  number_participantsMinim dolor commodo
  notification
  approval_date13-01-2025
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted22-01-2025
  unsubmitted1
  initial_date_submitted22-01-2025
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonThis is approved
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice324073
  modified2025-02-13 08:07:46
  created2025-01-22 11:13:13
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id92
  application_id159
  given_nameHiroko Lewis
  middle_nameTatyana Medina
  family_nameCastor Gallagher
  qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
  professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
  telephone+1 (322) 766-3057
  emailtipyhuqo@mailinator.com
  investigator_roleprincipal
  created2025-01-13 12:13:08
  modified2025-02-13 08:07:46
  SiteDetail(array)
  0(array)
  id1710
  application_id159
  county_id38
  site_nameAhmed Trujillo
  physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
  contact_detailsP.O. Box 10
  contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
  site_capacity(null)
  misc(null)
  created2025-01-13 12:13:08
  modified2025-02-13 08:07:46
  County(array)
  id38
  county_nameVihiga
  created2012-06-15 10:26:37
  modified2012-06-15 10:26:37
  Sponsor(array)
  0(array)
  id40
  application_id159
  sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
  sponsor_typeLocal Kenyan Investigator
  contact_personDolorem mollitia id quis provident error voluptatem voluptate
  addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
  telephone_number+1 (666) 325-1183
  fax_number+1 (314) 248-5575
  cell_number+1 (134) 102-6236
  email_addresstuhokelyh@mailinator.com
  created2025-01-13 12:13:08
  modified2025-02-13 08:07:46
  PublicAction(array)
  labelApproved
  date13-01-2025
  3(array)
  Application(array)
  id160
  user_id89
  application_id118
  is_child1
  trial_status_id(null)
  trial_status_date(null)
  total_sites5
  abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
  study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
  short_titleVirunex-3 Trial for Novacov-24
  protocol_noECCT/25/01/09 - DLoop
  reference_no1234redwsqa
  version_nov1
  date_of_protocol01-01-2025
  study_drugVirunex-3
  disease_conditionNovacov-24 Virus Infection
  product_type_biologicals1
  product_type_proteins0
  product_type_immunologicals1
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorNo
  comparator_name
  comparator_registered
  comparator_countries
  ecct_not_applicable0
  ecct_ref_number
  email_addressjkiprotich@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
  declaration_date110-01-2025
  declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
  declaration_date209-01-2025
  protocol_not_ai_generated0
  placebo_presentYes
  study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  scope_diagnosis1
  scope_prophylaxis0
  scope_therapy0
  scope_safety0
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic1
  scope_bioequivalence0
  scope_dose_response1
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic1
  scope_others1
  scope_others_specifyIn odit voluptate fu
  trial_human_pharmacology0
  trial_administration_humans1
  trial_bioequivalence_study0
  trial_other1
  trial_other_specifyVoluptas veniam ut
  trial_therapeutic_exploratory0
  trial_therapeutic_confirmatory1
  trial_therapeutic_use1
  design_controlledYes
  site_capacity(null)
  staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_rejected
  other_details_regulatory_halted
  estimated_durationTempore id architecto quaerat ad vel
  design_controlled_randomisedNo
  design_controlled_openYes
  design_controlled_single_blindNo
  design_controlled_double_blindYes
  design_controlled_parallel_groupNo
  design_controlled_cross_overYes
  design_controlled_otherYes
  design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
  design_controlled_comparatorAut qui perspiciatis rei
  design_controlled_other_medicinalNo
  design_controlled_placeboNo
  design_controlled_medicinal_otherYes
  design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesYes
  multiple_member_states668
  number_of_sites9
  multi_country_listAdipisicing et numqu
  data_monitoring_committeeYes
  total_enrolment_per_siteVitae voluptatem se
  total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
  population_less_than_18_yearsYes
  population_uteroYes
  population_preterm_newbornYes
  population_newbornYes
  population_infant_and_toddlerNo
  population_childrenYes
  population_adolescentNo
  population_above_18Yes
  population_adultNo
  population_elderlyNo
  gender_female1
  gender_male0
  subjects_healthyNo
  subjects_patientsYes
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingNo
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenNo
  subjects_nursing_womenYes
  subjects_emergency_situationNo
  subjects_incapable_consentYes
  subjects_specifyId tempora omnis vol
  subjects_othersYes
  subjects_others_specifyUllam laborum Eos
  investigator1_given_nameIlliana Ferguson
  investigator1_middle_nameAllen Fox
  investigator1_family_nameYolanda Rivera
  investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
  investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
  investigator1_telephone+1 (621) 831-1153
  investigator1_emailqeryrilu@mailinator.com
  organisations_transferred_Yes
  number_participantsMinim dolor commodo
  notification
  approval_date13-01-2025
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted23-01-2025
  unsubmitted1
  initial_date_submitted23-01-2025
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonThis is approved
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice324073
  modified2025-04-11 06:23:35
  created2025-01-23 08:22:01
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id93
  application_id160
  given_nameHiroko Lewis
  middle_nameTatyana Medina
  family_nameCastor Gallagher
  qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
  professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
  telephone+1 (322) 766-3057
  emailtipyhuqo@mailinator.com
  investigator_roleprincipal
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:03
  SiteDetail(array)
  0(array)
  id1711
  application_id160
  county_id38
  site_nameAhmed Trujillo
  physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
  contact_detailsP.O. Box 10
  contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
  site_capacity(null)
  misc(null)
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:03
  County(array)
  id38
  county_nameVihiga
  created2012-06-15 10:26:37
  modified2012-06-15 10:26:37
  Sponsor(array)
  0(array)
  id41
  application_id160
  sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
  sponsor_typeLocal Kenyan Investigator
  contact_personDolorem mollitia id quis provident error voluptatem voluptate
  addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
  telephone_number+1 (666) 325-1183
  fax_number+1 (314) 248-5575
  cell_number+1 (134) 102-6236
  email_addresstuhokelyh@mailinator.com
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:03
  PublicAction(array)
  labelApproved
  date13-01-2025
  4(array)
  Application(array)
  id118
  user_id29
  application_id(null)
  is_child0
  trial_status_id7
  trial_status_date(null)
  total_sites5
  abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
  study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
  short_titleVirunex-3 Trial for Novacov-24
  protocol_noECCT/25/01/09- KPCTYn
  reference_no1234redwsqa
  version_nov1
  date_of_protocol01-01-2025
  study_drugVirunex-3
  disease_conditionNovacov-24 Virus Infection
  product_type_biologicals1
  product_type_proteins0
  product_type_immunologicals1
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorNo
  comparator_name
  comparator_registered
  comparator_countries
  ecct_not_applicable0
  ecct_ref_number
  email_addressjkiprotich@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
  declaration_date110-01-2025
  declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
  declaration_date209-01-2025
  protocol_not_ai_generated0
  placebo_presentYes
  study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  scope_diagnosis1
  scope_prophylaxis0
  scope_therapy0
  scope_safety0
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic1
  scope_bioequivalence0
  scope_dose_response1
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic1
  scope_others1
  scope_others_specifyIn odit voluptate fu
  trial_human_pharmacology0
  trial_administration_humans1
  trial_bioequivalence_study0
  trial_other1
  trial_other_specifyVoluptas veniam ut
  trial_therapeutic_exploratory0
  trial_therapeutic_confirmatory1
  trial_therapeutic_use1
  design_controlledYes
  site_capacity(null)
  staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
  other_details_regulatory_rejected
  other_details_regulatory_halted
  estimated_durationTempore id architecto quaerat ad vel
  design_controlled_randomisedNo
  design_controlled_openYes
  design_controlled_single_blindNo
  design_controlled_double_blindYes
  design_controlled_parallel_groupNo
  design_controlled_cross_overYes
  design_controlled_otherYes
  design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
  design_controlled_comparatorAut qui perspiciatis rei
  design_controlled_other_medicinalNo
  design_controlled_placeboNo
  design_controlled_medicinal_otherYes
  design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesYes
  multiple_member_states668
  number_of_sites9
  multi_country_listAdipisicing et numqu
  data_monitoring_committeeYes
  total_enrolment_per_siteVitae voluptatem se
  total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
  population_less_than_18_yearsYes
  population_uteroYes
  population_preterm_newbornYes
  population_newbornYes
  population_infant_and_toddlerNo
  population_childrenYes
  population_adolescentNo
  population_above_18Yes
  population_adultNo
  population_elderlyNo
  gender_female1
  gender_male0
  subjects_healthyNo
  subjects_patientsYes
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingNo
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenNo
  subjects_nursing_womenYes
  subjects_emergency_situationNo
  subjects_incapable_consentYes
  subjects_specifyId tempora omnis vol
  subjects_othersYes
  subjects_others_specifyUllam laborum Eos
  investigator1_given_nameIlliana Ferguson
  investigator1_middle_nameAllen Fox
  investigator1_family_nameYolanda Rivera
  investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
  investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
  investigator1_telephone+1 (621) 831-1153
  investigator1_emailqeryrilu@mailinator.com
  organisations_transferred_Yes
  number_participantsMinim dolor commodo
  notification
  approval_date13-01-2025
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted07-01-2025
  unsubmitted1
  initial_date_submitted07-01-2025
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonThis is approved
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice324073
  modified2025-02-14 10:11:54
  created2024-10-17 10:21:33
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id87
  application_id118
  given_nameHiroko Lewis
  middle_nameTatyana Medina
  family_nameCastor Gallagher
  qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
  professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
  telephone+1 (322) 766-3057
  emailtipyhuqo@mailinator.com
  investigator_roleprincipal
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:58
  SiteDetail(array)
  0(array)
  id1707
  application_id118
  county_id38
  site_nameAhmed Trujillo
  physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
  contact_detailsP.O. Box 10
  contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
  site_capacity(null)
  misc(null)
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:58
  County(array)
  id38
  county_nameVihiga
  created2012-06-15 10:26:37
  modified2012-06-15 10:26:37
  Sponsor(array)
  0(array)
  id36
  application_id118
  sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
  sponsor_typeLocal Kenyan Investigator
  contact_personDolorem mollitia id quis provident error voluptatem voluptate
  addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
  telephone_number+1 (666) 325-1183
  fax_number+1 (314) 248-5575
  cell_number+1 (134) 102-6236
  email_addresstuhokelyh@mailinator.com
  created2025-01-13 12:13:08
  modified2025-02-06 10:49:58
  PublicAction(array)
  labelApproved
  date13-01-2025
  5(array)
  Application(array)
  id43
  user_id26
  application_id(null)
  is_child0
  trial_status_id(null)
  trial_status_date(null)
  total_sites(null)
  abstract_of_study<div>\n This randomized, double-blind, placebo-controlled study aimed to evaluate the safety, efficacy, and pharmacokinetics of Albenimol in adults diagnosed with depression. A total of [Number of Participants] participants were randomly assigned to receive either Albenimol or a placebo for 3years . The primary endpoints included changes in depressive symptoms as measured by standardized rating scales, as well as the incidence of adverse events. Secondary endpoints included pharmacokinetic parameters to evaluate the drug's absorption, distribution, metabolism, and excretion.</div>\n<div>\n </div>\n<div>\n The results indicated that Albenimol was well-tolerated, with a safety profile comparable to placebo. The most common adverse events reported were [List of Common Adverse Events]. Efficacy analyses suggested a significant reduction in depressive symptoms in the Albenimol group compared to placebo. Specifically, Albenimol demonstrated a [Percentage] reduction in the [Name of Rating Scale] score compared to [Percentage] reduction with placebo (p < 0.001).</div>\n<div>\n </div>\n<div>\n Pharmacokinetic data revealed Albenimol's predictable and consistent profile, with [Parameter] being [Value]. The results of this study support the further investigation of Albenimol as a potential treatment for depression. Additional research is warranted to confirm these findings and establish the long-term safety and efficacy of Albenimol in this population.</div>\n
  study_title<p>\n </p>\n<div class=\"mt-1 flex gap-3 empty:hidden juice:-ml-3\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; margin-top: 0.25rem; display: flex; gap: 0.75rem; margin-left: -0.75rem;\">\n <div class=\"items-center justify-start rounded-xl p-1 flex\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; align-items: center; justify-content: flex-start; border-radius: 0.75rem; padding: 0.25rem;\">\n <div class=\"flex items-center\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; align-items: center;\">\n <span data-state=\"closed\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;\"><button class=\"rounded-lg text-token-text-secondary hover:bg-token-main-surface-secondary\" style=\"border-width: 0px; border-style: solid; border-color: rgb(227, 227, 227); --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; font-feature-settings: inherit; font-family: inherit; font-size: 16px; font-variation-settings: inherit; font-weight: inherit; letter-spacing: inherit; line-height: inherit; margin: 0px; padding: 0px; appearance: button; background-image: none; cursor: pointer; border-radius: 0.5rem;\"><span class=\"flex h-[30px] w-[30px] items-center justify-center\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; height: 30px; width: 30px; align-items: center; justify-content: center;\"><svg class=\"icon-md-heavy\" fill=\"none\" height=\"24\" viewbox=\"0 0 24 24\" width=\"24\" xmlns=\"http://www.w3.org/2000/svg\"><path clip-rule=\"evenodd\" d=\"M7 5a3 3 0 0 1 3-3h9a3 3 0 0 1 3 3v9a3 3 0 0 1-3 3h-2v2a3 3 0 0 1-3 3H5a3 3 0 0 1-3-3v-9a3 3 0 0 1 3-3h2zm2 2h5a3 3 0 0 1 3 3v5h2a1 1 0 0 0 1-1V5a1 1 0 0 0-1-1h-9a1 1 0 0 0-1 1zM5 9a1 1 0 0 0-1 1v9a1 1 0 0 0 1 1h9a1 1 0 0 0 1-1v-9a1 1 0 0 0-1-1z\" fill=\"currentColor\" fill-rule=\"evenodd\"></path></svg></span></button></span><span data-state=\"closed\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;\"><button class=\"rounded-lg text-token-text-secondary hover:bg-token-main-surface-secondary\" style=\"border-width: 0px; border-style: solid; border-color: rgb(227, 227, 227); --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; font-feature-settings: inherit; font-family: inherit; font-size: 16px; font-variation-settings: inherit; font-weight: inherit; letter-spacing: inherit; line-height: inherit; margin: 0px; padding: 0px; appearance: button; background-image: none; cursor: pointer; border-radius: 0.5rem;\"><span class=\"flex h-[30px] w-[30px] items-center justify-center\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; height: 30px; width: 30px; align-items: center; justify-content: center;\"><svg class=\"icon-md-heavy\" fill=\"none\" height=\"24\" viewbox=\"0 0 24 24\" width=\"24\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M3.07 10.876C3.623 6.436 7.41 3 12 3a9.15 9.15 0 0 1 6.012 2.254V4a1 1 0 1 1 2 0v4a1 1 0 0 1-1 1H15a1 1 0 1 1 0-2h1.957A7.15 7.15 0 0 0 12 5a7 7 0 0 0-6.946 6.124 1 1 0 1 1-1.984-.248m16.992 1.132a1 1 0 0 1 .868 1.116C20.377 17.564 16.59 21 12 21a9.15 9.15 0 0 1-6-2.244V20a1 1 0 1 1-2 0v-4a1 1 0 0 1 1-1h4a1 1 0 1 1 0 2H7.043A7.15 7.15 0 0 0 12 19a7 7 0 0 0 6.946-6.124 1 1 0 0 1 1.116-.868\" fill=\"currentColor\"></path></svg></span></button></span>\n <div class=\"flex\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex;\">\n <span data-state=\"closed\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;\"><button class=\"rounded-lg text-token-text-secondary hover:bg-token-main-surface-secondary\" style=\"border-width: 0px; border-style: solid; border-color: rgb(227, 227, 227); --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; font-feature-settings: inherit; font-family: inherit; font-size: 16px; font-variation-settings: inherit; font-weight: inherit; letter-spacing: inherit; line-height: inherit; margin: 0px; padding: 0px; appearance: button; background-image: none; cursor: pointer; border-radius: 0.5rem;\"><span class=\"flex h-[30px] w-[30px] items-center justify-center\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; height: 30px; width: 30px; align-items: center; justify-content: center;\"><svg class=\"icon-md-heavy\" fill=\"none\" height=\"24\" viewbox=\"0 0 24 24\" width=\"24\" xmlns=\"http://www.w3.org/2000/svg\"><path clip-rule=\"evenodd\" d=\"M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z\" fill=\"currentColor\" fill-rule=\"evenodd\"></path></svg></span></button></span></div>\n <span data-state=\"closed\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;\"><button aria-expanded=\"false\" aria-haspopup=\"menu\" class=\"cursor-pointer rounded-md px-1 text-token-text-secondary h-[30px] hover:bg-token-main-surface-secondary\" data-state=\"closed\" id=\"radix-:ror:\" style=\"border-width: 0px; border-style: solid; border-color: rgb(227, 227, 227); --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; font-feature-settings: inherit; font-family: inherit; font-size: 16px; font-variation-settings: inherit; font-weight: inherit; letter-spacing: inherit; line-height: inherit; margin: 0px; padding: 0px 0.25rem; appearance: button; background-image: none; cursor: pointer; height: 30px; border-radius: 0.375rem;\" type=\"button\">\n <div class=\"flex items-center pb-0.5 juice:pb-0\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; align-items: center; padding-bottom: 0px;\">\n <div class=\"[&_svg]:h-full [&_svg]:w-full icon-md h-4 w-4\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; stroke-width: 1.5; flex-shrink: 0; height: 1rem; width: 1rem; color: rgb(180, 180, 180); font-family: ui-sans-serif, -apple-system, system-ui, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, Helvetica, "Apple Color Emoji", Arial, "Segoe UI Emoji", "Segoe UI Symbol"; background-color: rgb(33, 33, 33);\">\n <svg fill=\"none\" height=\"24\" viewbox=\"0 0 24 24\" width=\"24\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M13.091 4.246 4.682 14H11a1 1 0 0 1 .973 1.23l-1.064 4.524L19.318 10H13a1 1 0 0 1-.973-1.229l1.064-4.525Zm-.848-2.08c1.195-1.386 3.448-.238 3.029 1.544L14.262 8h5.056c1.711 0 2.632 2.01 1.514 3.306l-9.075 10.528c-1.195 1.386-3.448.238-3.029-1.544L9.738 16H4.681c-1.711 0-2.632-2.01-1.514-3.306l9.075-10.527Z\" fill=\"currentColor\"></path></svg></div>\n </div>\n </button></span></div>\n </div>\n</div>\n<div class=\"flex flex-grow flex-col max-w-full\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; max-width: 100%; flex-grow: 1; flex-direction: column;\">\n <div class=\"min-h-[20px] text-message flex flex-col items-start whitespace-pre-wrap break-words [.text-message+&]:mt-5 juice:w-full juice:items-end overflow-x-auto gap-2\" data-message-author-role=\"assistant\" data-message-id=\"42991a18-c7df-46ed-9200-c092ad9249fd\" dir=\"auto\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; min-height: 20px; flex-direction: column; align-items: flex-end; gap: 0.5rem; overflow-x: auto; white-space-collapse: preserve; overflow-wrap: break-word; width: 712px;\">\n <div class=\"flex w-full flex-col gap-1 juice:empty:hidden juice:first:pt-[3px]\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; width: 712px; flex-direction: column; gap: 0.25rem; padding-top: 3px;\">\n <div class=\"markdown prose w-full break-words dark:prose-invert dark\" style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; --text-primary: var(--gray-100); --text-secondary: var(--gray-300); --text-tertiary: var(--gray-400); --text-quaternary: var(--gray-500); --text-error: var(--red-500); --border-light: hsla(0,0%,100%,.1); --border-medium: hsla(0,0%,100%,.15); --border-heavy: hsla(0,0%,100%,.2); --border-xheavy: hsla(0,0%,100%,.25); --main-surface-primary: var(--gray-800); --main-surface-secondary: var(--gray-750); --main-surface-tertiary: var(--gray-700); --sidebar-surface-primary: var(--gray-900); --sidebar-surface-secondary: var(--gray-800); --sidebar-surface-tertiary: var(--gray-750); --link: #7ab7ff; --link-hover: #5e83b3; color: var(--tw-prose-body); max-width: none; --tw-prose-body: var(--tw-prose-invert-body); --tw-prose-headings: var(--tw-prose-invert-headings); --tw-prose-lead: var(--tw-prose-invert-lead); --tw-prose-links: var(--tw-prose-invert-links); --tw-prose-bold: var(--tw-prose-invert-bold); --tw-prose-counters: var(--tw-prose-invert-counters); --tw-prose-bullets: var(--tw-prose-invert-bullets); --tw-prose-hr: var(--tw-prose-invert-hr); --tw-prose-quotes: var(--tw-prose-invert-quotes); --tw-prose-quote-borders: var(--tw-prose-invert-quote-borders); --tw-prose-captions: var(--tw-prose-invert-captions); --tw-prose-code: var(--tw-prose-invert-code); --tw-prose-pre-code: var(--tw-prose-invert-pre-code); --tw-prose-pre-bg: var(--tw-prose-invert-pre-bg); --tw-prose-th-borders: var(--tw-prose-invert-th-borders); --tw-prose-td-borders: var(--tw-prose-invert-td-borders); --tw-prose-invert-body: var(--text-primary); --tw-prose-invert-headings: var(--text-primary); --tw-prose-invert-lead: var(--text-primary); --tw-prose-invert-links: var(--text-primary); --tw-prose-invert-bold: var(--text-primary); --tw-prose-invert-counters: var(--text-primary); --tw-prose-invert-bullets: var(--text-primary); --tw-prose-invert-hr: var(--border-xheavy); --tw-prose-invert-quotes: var(--text-primary); --tw-prose-invert-quote-borders: #374151; --tw-prose-invert-captions: var(--text-secondary); --tw-prose-invert-code: var(--text-primary); --tw-prose-invert-pre-code: #d1d5db; --tw-prose-invert-pre-bg: rgba(0,0,0,.5); --tw-prose-invert-th-borders: #4b5563; --tw-prose-invert-td-borders: #374151; font-size: 1rem; line-height: 1.75; width: 712px; overflow-wrap: break-word;\">\n <p style=\"border: 0px solid rgb(227, 227, 227); box-sizing: border-box; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(69,89,164,.5); --tw-ring-offset-shadow: 0 0 transparent; --tw-ring-shadow: 0 0 transparent; --tw-shadow: 0 0 transparent; --tw-shadow-colored: 0 0 transparent; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; margin: 0px;\">\n <span style=\"font-family:bookman old style,serif;\">"Exploring the Therapeutic Potential of Albenimol: A Review of Its Antiparasitic and Anticancer Properties"</span></p>\n <div>\n </div>\n </div>\n </div>\n </div>\n</div>\n<p>\n </p>\n
  laymans_summary<div>\n <span style=\"font-family:bookman old style,serif;\">Albenimol is a drug that has shown promise in various studies for its potential therapeutic benefits. It belongs to a class of medications known as benzimidazoles, which have been used in the treatment of various conditions, including parasitic infections and certain cancers. Albenimol is thought to exert its effects by interfering with the growth and reproduction of cells, particularly those of parasites or cancerous cells.</span></div>\n<div>\n </div>\n<div>\n <span style=\"font-family:bookman old style,serif;\">One area of interest in Albenimol research is its potential as an anthelmintic, a type of medication used to treat parasitic worm infections. Parasitic worms, or helminths, can infect various organs in the body, causing a range of symptoms and health problems. Albenimol has been studied for its ability to effectively kill these parasites, thereby helping to alleviate the symptoms of infection and improve overall health.</span></div>\n<div>\n </div>\n<div>\n <span style=\"font-family:bookman old style,serif;\">In addition to its potential as an anthelmintic, Albenimol has also been investigated for its anticancer properties. Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Albenimol is believed to inhibit the growth of cancer cells by interfering with their cell division process, ultimately leading to their death. This makes Albenimol a potentially valuable medication in the treatment of certain types of cancer.</span></div>\n<div>\n </div>\n<div>\n <span style=\"font-family:bookman old style,serif;\">One of the key advantages of Albenimol is its relatively low toxicity compared to other medications. This means that it can be used at higher doses without causing significant harm to the patient. However, like all medications, Albenimol does have side effects, which can vary depending on the dose and duration of treatment. Common side effects of Albenimol include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, more serious side effects such as liver toxicity or allergic reactions may occur.</span></div>\n<div>\n </div>\n<div>\n <span style=\"font-family:bookman old style,serif;\">The use of Albenimol in clinical practice is still being explored, and more research is needed to fully understand its potential benefits and risks. Clinical trials are underway to evaluate the safety and efficacy of Albenimol in various patient populations, including those with parasitic infections and cancer. These studies will help to determine the optimal dose and treatment duration for Albenimol, as well as its long-term effects on patient outcomes.</span></div>\n<div>\n </div>\n<div>\n <span style=\"font-family:bookman old style,serif;\">In conclusion, Albenimol is a promising drug with potential therapeutic benefits in the treatment of parasitic infections and certain cancers. While more research is needed to fully understand its effects, early studies suggest that Albenimol could be a valuable addition to the arsenal of medications used to treat these conditions. As research into Albenimol continues, it is hoped that this drug will become an important tool in the fight against parasitic infections and cancer, ultimately improving the lives of patients worldwide.</span></div>\n
  short_title\"Exploring Albenimol
  protocol_noECCT/24/05/03
  reference_no(null)
  version_no1.0
  date_of_protocol24-05-2024
  study_drugAlbenimol
  disease_conditionDepression
  product_type_biologicals1
  product_type_proteins1
  product_type_immunologicals0
  product_type_vaccines0
  product_type_hormones0
  product_type_toxoid0
  product_type_chemical0
  product_type_medical_device0
  product_type_chemical_name
  product_type_medical_device_name
  comparatorYes
  comparator_nameComparatorX
  comparator_registeredYes
  comparator_countriesUnited States\nUnited Kingdom\nGermany\nFrance\nJapan\nAustralia\nCanada\nBrazil\nSouth Africa\nIndia
  ecct_not_applicable0
  ecct_ref_number
  email_addressjayoma@intellisoftkenya.com
  applicant_covering_letter1
  applicant_protocol1
  applicant_patient_information1
  applicant_investigators_brochure1
  applicant_investigators_cv1
  applicant_signed_declaration1
  applicant_financial_declaration1
  applicant_gmp_certificate1
  applicant_indemnity_cover1
  applicant_opinion_letter1
  applicant_approval_letter1
  applicant_statement1
  applicant_participating_countries(null)
  applicant_addendum1
  applicant_fees1
  applicant_complete_form(null)
  applicant_impd1
  applicant_prev_data1
  applicant_stability_data1
  applicant_analysis_cert1
  applicant_pictorial_sample1
  applicant_gcp_training1
  applicant_dsmb_charter1
  applicant_detailed_budget1
  applicant_indemnity_pi1
  applicant_practice_license1
  applicant_registration_ctr(null)
  applicant_pan_african1
  applicant_hard_copies(null)
  applicant_signed_checklist1
  statistical_analysis_plan1
  applicant_contractual_agreement1
  declaration_applicant+238394047
  declaration_date124-05-2024
  declaration_principal_investigatorJames Kware
  declaration_date224-05-2024
  protocol_not_ai_generated0
  placebo_presentNo
  study_objectives<div>\n Evaluate the efficacy of the intervention in reducing symptoms and improving overall health outcomes, assess the safety profile of the treatment, including any adverse effects or complications, investigate the impact of the intervention on quality of life, including physical, mental, and social well-being, determine the optimal dosage and administration schedule of the drug to maximize effectiveness and minimize side effects, explore the long-term effects of the treatment to assess its sustainability and durability, compare the intervention with standard care or other existing treatments to determine its relative effectiveness, identify predictors of treatment response to personalize and optimize patient care, assess adherence to the treatment regimen to understand patient compliance and its impact on outcomes, evaluate the cost-effectiveness of the intervention to inform healthcare resource allocation and policy decisions, investigate the mechanism of action of the drug to better understand its effects on the body, assess the feasibility of implementing the intervention in real-world settings, considering logistical and practical challenges, determine the pharmacokinetics of the drug, including its absorption, distribution, metabolism, and excretion in the body, assess the impact of the intervention on biomarkers, such as blood tests or imaging studies, to monitor disease progression or treatment response, investigate the effect of the intervention on disease progression to assess its potential to slow or halt the course of the disease, explore the role of genetic factors in treatment response to personalize therapy and improve outcomes, assess the impact of the intervention on healthcare utilization, including hospitalizations, emergency department visits, and outpatient visits, determine the effect of the intervention on comorbid conditions, such as other medical or mental health conditions that may co-occur with the primary condition, evaluate the impact of the intervention on caregiver burden, including the physical, emotional, and financial strain on caregivers, assess the effect of the intervention on functional outcomes, such as the ability to perform daily activities or participate in social and recreational activities, investigate the impact of the intervention on patient satisfaction and quality of care, evaluate the impact of the intervention on healthcare costs, including direct medical costs and indirect costs such as lost productivity, determine the effect of the intervention on treatment adherence and persistence, including factors that may influence patient compliance, assess the effect of the intervention on mental health outcomes, such as anxiety, depression, or other psychological symptoms, explore the impact of the intervention on social functioning, including relationships, work, and community involvement, evaluate the impact of the intervention on physical health, including symptoms, physical functioning, and overall health status, assess the effect of the intervention on healthcare resource utilization, including hospitalizations, emergency department visits, and outpatient services, investigate the impact of the intervention on healthcare disparities, including differences in access to care and health outcomes among different populations, evaluate the impact of the intervention on health-related quality of life, including physical, mental, and social aspects of well-being, determine the effect of the intervention on healthcare access, including barriers to care and the availability of services, assess the effect of the intervention on patient-reported outcomes, such as symptoms, quality of life, and treatment satisfaction, investigate the impact of the intervention on healthcare costs, including direct medical costs and indirect costs such as lost productivity, assess the effect of the intervention on caregiver outcomes, including caregiver burden, quality of life, and mental health, evaluate the impact of the intervention on healthcare utilization, including hospitalizations, emergency department visits, and outpatient services, determine the effect of the intervention on treatment satisfaction, including patient preferences and experiences with care, investigate the impact of the intervention on healthcare disparities, including differences in access to care and health outcomes among different populations, assess the effect of the intervention on healthcare access, including barriers to care and the availability of services, evaluate the impact of the intervention on health-related quality of life, including physical, mental, and social aspects of well-being, determine the effect of the intervention on patient-reported outcomes, such as symptoms, quality of life, and treatment satisfaction, investigate the impact of the intervention on healthcare costs, including direct medical costs and indirect costs such as lost productivity, assess the effect of the intervention on caregiver outcomes, including caregiver burden, quality of life, and mental health, evaluate the impact of the intervention on healthcare utilization, including hospitalizations, emergency department visits, and outpatient services, determine the effect of the intervention on treatment satisfaction, including patient preferences and experiences with care, investigate the impact of the intervention on healthcare disparities, including differences in access to care and health outcomes among different populations, assess the effect of the intervention on healthcare access, including barriers to care and the availability of services, evaluate the impact of the intervention on health-related quality of life, including physical, mental, and social aspects of well-being, determine the effect of the intervention on patient-reported outcomes, such as symptoms, quality of life, and treatment satisfaction, investigate the impact of the intervention on healthcare costs, including direct medical costs and indirect costs such as lost productivity, assess the effect of the intervention on caregiver outcomes, including caregiver burden, quality of life, and mental health, evaluate the impact of the intervention on healthcare utilization, including hospitalizations, emergency department visits,</div>\n
  principal_inclusion_criteria<div>\n Inclusion criteria are essential factors that determine whether a participant is eligible to participate in a clinical trial or study. Here are five principal inclusion criteria for a hypothetical study:</div>\n<div>\n </div>\n<div>\n 1. Age and Gender: Participants must be between 18 and 65 years old, of any gender, to ensure a diverse sample that represents the general population affected by the condition under study. This criterion is important to establish a baseline understanding of how the intervention impacts different age groups and genders.</div>\n<div>\n </div>\n<div>\n 2. Diagnosis of the Condition: Participants must have a confirmed diagnosis of the target condition, as determined by specific diagnostic criteria (e.g., clinical symptoms, laboratory tests, imaging studies). This criterion ensures that participants have the condition being studied, allowing researchers to assess the intervention's effectiveness in treating or managing the condition.</div>\n<div>\n </div>\n<div>\n 3. Treatment History: Participants must have a documented history of inadequate response or intolerance to standard treatments for the condition. This criterion helps identify individuals who may benefit from alternative or experimental interventions and ensures that participants have a genuine need for the new treatment approach.</div>\n<div>\n </div>\n<div>\n 4.Ability to Provide Informed Consent: Participants must be able to understand the study's purpose, risks, and benefits and provide informed consent to participate. This criterion is essential to protect participants' rights and ensure that they understand the nature of their involvement in the study.</div>\n<div>\n </div>\n<div>\n 5. Willingness to Comply with Study Requirements: Participants must be willing and able to comply with all study procedures, including attending scheduled visits, taking medications as prescribed, and completing study assessments. This criterion helps ensure the study's integrity and reliability by minimizing dropouts and ensuring data completeness.</div>\n<div>\n </div>\n<div>\n These inclusion criteria help define the characteristics of the participants who will be included in the study, ensuring that the results are meaningful and applicable to the target population.</div>\n
  principal_exclusion_criteria<div>\n </div>\n<div>\n 1. **Pregnancy or Lactation:** Women who are pregnant, breastfeeding, or planning to become pregnant during the study period may be excluded due to potential risks to the fetus or infant from the investigational treatment.</div>\n<div>\n </div>\n<div>\n 2. **Severe Comorbidities:** Individuals with severe comorbid conditions that could interfere with the study outcomes or pose a risk to their safety may be excluded. Examples include severe cardiovascular disease, uncontrolled diabetes, or active cancer.</div>\n<div>\n </div>\n<div>\n 3. **Psychiatric Disorders:** Individuals with severe psychiatric disorders, such as schizophrenia or bipolar disorder, may be excluded due to potential challenges in assessing the intervention's effects or ensuring compliance with study procedures.</div>\n<div>\n </div>\n<div>\n 4. **Substance Abuse:** Individuals with a history of substance abuse or dependence, such as alcohol or drug abuse, may be excluded due to potential interactions between the investigational treatment and substances of abuse.</div>\n<div>\n </div>\n<div>\n 5. **Previous Participation in Similar Studies:** Individuals who have participated in a similar study involving the investigational treatment or a closely related intervention may be excluded to avoid confounding effects from previous exposure.</div>\n<div>\n </div>\n<div>\n 6. **Allergy or Sensitivity:** Individuals with known allergies or sensitivities to the investigational treatment or its components may be excluded due to the risk of allergic reactions.</div>\n<div>\n </div>\n<div>\n 7. **Inability to Provide Informed Consent:** Individuals who are unable to understand the study requirements, risks, and benefits, or provide informed consent, may be excluded to ensure that participants can fully understand and voluntarily participate in the study.</div>\n<div>\n </div>\n<div>\n 8. **Use of Certain Medications:** Individuals taking medications that could interact with the investigational treatment or affect the study outcomes may be excluded. Examples include certain antibiotics, anticoagulants, or immunosuppressants.</div>\n<div>\n </div>\n<div>\n 9. **Unwillingness to Comply with Study Requirements:** Individuals who are unwilling or unable to comply with study procedures, such as attending scheduled visits or completing study assessments, may be excluded to ensure the study's integrity and reliability.</div>\n
  primary_end_points<div>\n Â </div>\n<div>\n 1. **Clinical Response Rate:** The primary endpoint is the proportion of patients who achieve a predefined clinical response, such as a reduction in symptoms or improvement in a specific clinical parameter, after a specified treatment period.</div>\n<div>\n Â </div>\n<div>\n 2. **Disease Progression:** Another primary endpoint is the rate of disease progression, as measured by changes in biomarkers, imaging studies, or clinical assessments, over the study period.</div>\n<div>\n Â </div>\n<div>\n 3. **Survival Rate:** The study may also assess the survival rate of patients treated with the new drug compared to standard treatment or placebo over a specified follow-up period.</div>\n<div>\n Â </div>\n<div>\n 4. **Quality of Life Improvement:** The primary endpoint could include improvements in quality of life, as measured by validated questionnaires or assessments, in patients receiving the new drug compared to those receiving standard treatment or placebo.</div>\n<div>\n Â </div>\n<div>\n 5. **Disease-Free Survival:** Another primary endpoint is the duration of time during which patients remain free of disease recurrence or progression after receiving treatment.</div>\n<div>\n Â </div>\n<div>\n 6. **Symptom Relief:** The study may assess the degree of symptom relief experienced by patients, as measured by changes in symptom severity scores or patient-reported outcomes, after treatment with the new drug.</div>\n<div>\n Â </div>\n<div>\n 7. **Functional Improvement:** The primary endpoint could include improvements in physical or cognitive function, as measured by standardized assessments, in patients receiving the new drug compared to standard treatment or placebo.</div>\n<div>\n Â </div>\n<div>\n 8. **Safety and Tolerability:** The study will also evaluate the safety and tolerability of the new drug, with the primary endpoint being the incidence and severity of adverse events reported by patients during the study period.</div>\n<div>\n Â </div>\n<div>\n These primary endpoints are critical for evaluating the efficacy, safety, and impact of the new drug on patients with the target medical condition.</div>\n
  scope_diagnosis0
  scope_prophylaxis1
  scope_therapy1
  scope_safety0
  scope_efficacy0
  scope_pharmacokinetic0
  scope_pharmacodynamic1
  scope_bioequivalence0
  scope_dose_response0
  scope_pharmacogenetic0
  scope_pharmacogenomic0
  scope_pharmacoecomomic0
  scope_others0
  scope_others_specify
  trial_human_pharmacology0
  trial_administration_humans1
  trial_bioequivalence_study0
  trial_other0
  trial_other_specify
  trial_therapeutic_exploratory1
  trial_therapeutic_confirmatory1
  trial_therapeutic_use0
  design_controlledYes
  site_capacity(null)
  staff_numbers<div>\n 1. Mombasa General Hospital:</div>\n<div>\n Â Â - Capacity: 300 beds</div>\n<div>\n Â Â - Number of Staff: 250</div>\n<div>\n Â Â Â - Dr. Jane Kinyua (Medical Director, MBChB, MPH, 15 years experience)</div>\n<div>\n Â Â Â - Sarah Wambui (Head Nurse, BScN, 10 years experience)</div>\n<div>\n Â Â Â - John Kamau (Lab Technician, Diploma in Medical Laboratory Sciences, 8 years experience)</div>\n<div>\n Â Â - Site Facilities: Operating theaters, laboratory, pharmacy, radiology department</div>\n<div>\n Â Â - Emergency Facilities: Emergency department, ambulance services</div>\n<div>\n Â Â - Other Infrastructure: Conference rooms, cafeteria</div>\n<div>\n Â </div>\n<div>\n 2. Kisumu Medical Center:</div>\n<div>\n Â Â - Capacity: 250 beds</div>\n<div>\n Â Â - Number of Staff: 200</div>\n<div>\n Â Â Â - Dr. Peter Otieno (Medical Officer, MBChB, 8 years experience)</div>\n<div>\n Â Â Â - Mercy Auma (Nurse, Diploma in Nursing, 5 years experience)</div>\n<div>\n Â Â Â - Joseph Ochieng (Pharmacist, BPharm, 7 years experience)</div>\n<div>\n Â Â - Site Facilities: Outpatient department, maternity ward, pediatric ward</div>\n<div>\n Â Â - Emergency Facilities: Emergency room, ICU</div>\n<div>\n Â Â - Other Infrastructure: Library, staff quarters</div>\n<div>\n Â </div>\n<div>\n 3. Nakuru Community Hospital:</div>\n<div>\n Â Â - Capacity: 150 beds</div>\n<div>\n Â Â - Number of Staff: 120</div>\n<div>\n Â Â Â - Dr. Susan Mwangi (Hospital Administrator, MBA, 12 years experience)</div>\n<div>\n Â Â Â - James Kariuki (Clinical Officer, Diploma in Clinical Medicine, 9 years experience)</div>\n<div>\n Â Â Â - Faith Njeri (Lab Technologist, Diploma in Medical Laboratory Sciences, 5 years experience)</div>\n<div>\n Â Â - Site Facilities: Radiology department, physiotherapy unit, dental clinic</div>\n<div>\n Â Â - Emergency Facilities: Casualty department, ambulance services</div>\n<div>\n Â Â - Other Infrastructure: Staff canteen, recreational facilities</div>\n<div>\n Â </div>\n<div>\n 4. Eldoret Health Center:</div>\n<div>\n Â Â - Capacity: 200 beds</div>\n<div>\n Â Â - Number of Staff: 180</div>\n<div>\n Â Â Â - Dr. David Kimani (Medical Superintendent, MBChB, MPH, 17 years experience)</div>\n<div>\n Â Â Â - Grace Chebet (Nurse, BScN, 10 years experience)</div>\n<div>\n Â Â Â - Charles Omondi (Pharmacist, BPharm, 12 years experience)</div>\n<div>\n Â Â - Site Facilities: Outpatient clinics, surgical unit, HIV/AIDS clinic</div>\n<div>\n Â Â - Emergency Facilities: Emergency room, ambulance services</div>\n<div>\n Â Â - Other Infrastructure: Auditorium, guest house for visitors</div>\n<div>\n Â </div>\n<div>\n 5. Thika District Hospital:</div>\n<div>\n Â Â - Capacity: 280 beds</div>\n<div>\n Â Â - Number of Staff: 220</div>\n<div>\n Â Â Â - Dr. Mercy Wanjiku (Head of Department, Pediatrics, MBChB, 13 years experience)</div>\n<div>\n Â Â Â - John Mwangi (Registered Nurse, BScN, 8 years experience)</div>\n<div>\n Â Â Â - Esther Njoki (Lab Technologist, Diploma in Medical Laboratory Sciences, 6 years experience)</div>\n<div>\n Â Â - Site Facilities: Maternity wing, laboratory, pharmacy</div>\n<div>\n Â Â - Emergency Facilities: Emergency department, ambulance services</div>\n<div>\n Â Â - Other Infrastructure: Staff gym, daycare center</div>\n<div>\n Â </div>\n<div>\n 6. Kitale Medical Clinic:</div>\n<div>\n Â Â - Capacity: 100 beds</div>\n<div>\n Â Â - Number of Staff: 80</div>\n<div>\n Â Â Â - Dr. James Mugo (Medical Officer, MBChB, 6 years experience)</div>\n<div>\n Â Â Â - Mary Njoroge (Nurse, Diploma in Nursing, 4 years experience)</div>\n<div>\n Â Â Â - Patrick Ochieng (Lab Technologist, Diploma in Medical Laboratory Sciences, 3 years experience)</div>\n<div>\n Â Â - Site Facilities: Outpatient services, laboratory, pharmacy</div>\n<div>\n Â Â - Emergency Facilities: Emergency room</div>\n<div>\n Â Â - Other Infrastructure: Waiting area, administrative offices</div>\n<div>\n Â </div>\n<div>\n 7. Machakos General Hospital:</div>\n<div>\n Â Â - Capacity: 220 beds</div>\n<div>\n Â Â - Number of Staff: 180</div>\n<div>\n Â Â Â - Dr. Alice Mutisya (Hospital Administrator, MBA, 10 years experience)</div>\n<div>\n Â Â Â - Paul Kimani (Clinical Officer, Diploma in Clinical Medicine, 7 years experience)</div>\n<div>\n Â Â Â - Grace Wambui (Lab Technologist, Diploma in Medical Laboratory Sciences, 5 years experience)</div>\n<div>\n Â Â - Site Facilities: Surgical unit, maternity wing, radiology department</div>\n<div>\n Â Â - Emergency Facilities: Emergency department, ambulance services</div>\n<div>\n Â Â - Other Infrastructure: Staff cafeteria, pharmacy, library</div>\n
  other_details_explanation<div>\n 1. **Access to a Diverse Patient Population:** Kenya's population is diverse, with a wide range of genetic, environmental, and lifestyle factors that can influence disease prevalence, progression, and treatment response. Conducting a trial in Kenya may allow researchers to study the effects of the investigational treatment in a population that is different from the sponsor's home country, potentially providing valuable insights into the treatment's efficacy and safety across different populations.</div>\n<div>\n </div>\n<div>\n 2. **Availability of Expertise:** Kenya has a growing healthcare infrastructure and a skilled workforce of healthcare professionals who are experienced in conducting clinical trials. Collaborating with Kenyan researchers and institutions can provide access to local expertise and resources that may enhance the quality and efficiency of the trial.</div>\n<div>\n </div>\n<div>\n 3. **Regulatory Environment:** Kenya has a well-established regulatory framework for clinical trials, which is aligned with international standards and guidelines. Conducting a trial in Kenya may streamline the regulatory approval process and facilitate the timely initiation and completion of the study.</div>\n<div>\n </div>\n<div>\n 4. **Patient Recruitment:** Conducting a trial in Kenya may offer access to a larger pool of eligible participants, which can be particularly beneficial for studies that require a diverse or specific patient population. Kenya's population size and demographic diversity make it an attractive location for patient recruitment.</div>\n<div>\n </div>\n<div>\n 5. **Cost-Effectiveness:** Conducting a trial in Kenya may be more cost-effective than in other countries, due to lower operational costs, including clinical trial site fees, healthcare costs, and staffing costs. This can be especially advantageous for sponsors looking to conduct large-scale or long-term trials.</div>\n<div>\n </div>\n<div>\n Overall, conducting a clinical trial in Kenya can offer several advantages, including access to a diverse patient population, local expertise, a supportive regulatory environment, and cost-effectiveness. These factors can contribute to the successful completion of the trial and the generation of valuable data that can benefit patients both in Kenya and globally.</div>\n
  other_details_regulatory_notapproved<p>\n P<span apple=\"\" color=\"\" font-size:=\"\" noto=\"\" segoe=\"\" style=\"background-color: rgb(33, 33, 33); color: rgb(236, 236, 236); font-family: ui-sans-serif, -apple-system, system-ui, \" ui=\"\" white-space-collapse:=\"\">harmacy and Poisons Board </span></p>\n
  other_details_regulatory_approved<div>\n 1. **United States (FDA):**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 10</div>\n<div>\n Â </div>\n<div>\n 2. **European Medicines Agency (EMA) - European Union:**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 8</div>\n<div>\n Â </div>\n<div>\n 3. **Australia (TGA):**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 5</div>\n<div>\n Â </div>\n<div>\n 4. **Canada (Health Canada):**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 4</div>\n<div>\n Â </div>\n<div>\n 5. **India (CDSCO):**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 6</div>\n<div>\n Â </div>\n<div>\n 6. **South Africa (SAHPRA):**</div>\n<div>\n Â Â - Date of Approval: May 24, 2024</div>\n<div>\n Â Â - Number of Sites: 3</div>\n
  other_details_regulatory_rejected<div>\n Â </div>\n<div>\n 1. **Incomplete or Insufficient Data:** If the trial application lacks essential information or the data provided is not comprehensive enough to assess the risks and benefits of the trial, it may be rejected.</div>\n<div>\n Â </div>\n<div>\n 2. **Safety Concerns:** If the regulatory authority or ethics committee determines that the investigational drug poses significant safety risks to participants, they may reject the trial to protect participant safety.</div>\n<div>\n Â </div>\n<div>\n 3. **Ethical Concerns:** If the trial design or procedures raise ethical issues, such as inadequate informed consent procedures, exploitation of vulnerable populations, or insufficient protection of participant rights, the trial may be rejected.</div>\n<div>\n Â </div>\n<div>\n 4. **Methodological Concerns:** If the trial design, including the sample size, randomization, or statistical analysis plan, is deemed inadequate or flawed, the trial may be rejected due to concerns about the validity and reliability of the results.</div>\n<div>\n Â </div>\n<div>\n 5. **Conflict of Interest:** If there are perceived conflicts of interest, such as financial relationships between the trial sponsor and investigators that could bias the study results, the trial may be rejected to ensure the integrity of the research.</div>\n<div>\n Â </div>\n<div>\n 6. **Regulatory Non-Compliance:** If the trial does not comply with regulatory requirements or guidelines, such as those related to Good Clinical Practice (GCP) or reporting of adverse events, it may be rejected until these issues are addressed.</div>\n
  other_details_regulatory_halted<p>\n /a</p>\n
  estimated_duration36
  design_controlled_randomisedYes
  design_controlled_openYes
  design_controlled_single_blindYes
  design_controlled_double_blindYes
  design_controlled_parallel_groupNo
  design_controlled_cross_overYes
  design_controlled_otherNo
  design_controlled_specify
  design_controlled_comparatorComparatorX
  design_controlled_other_medicinalNo
  design_controlled_placeboYes
  design_controlled_medicinal_otherNo
  design_controlled_medicinal_specify
  single_site_member_stateNo
  location_of_area
  single_site_physical_address
  single_site_contact_person
  single_site_telephone
  multiple_sites_member_stateYes
  multiple_countriesNo
  multiple_member_states
  number_of_sites12
  multi_country_list
  data_monitoring_committeeYes
  total_enrolment_per_site3000
  total_participants_worldwide3600000
  population_less_than_18_yearsYes
  population_uteroNo
  population_preterm_newbornNo
  population_newbornNo
  population_infant_and_toddlerNo
  population_childrenNo
  population_adolescentYes
  population_above_18Yes
  population_adultYes
  population_elderlyYes
  gender_female1
  gender_male0
  subjects_healthyYes
  subjects_patientsYes
  subjects_vulnerable_populationsYes
  subjects_women_child_bearingYes
  subjects_women_using_contraceptionYes
  subjects_pregnant_womenYes
  subjects_nursing_womenNo
  subjects_emergency_situationNo
  subjects_incapable_consentNo
  subjects_specify
  subjects_othersNo
  subjects_others_specify
  investigator1_given_nameSamuel
  investigator1_middle_name
  investigator1_family_nameMwangi
  investigator1_qualificationMBChB, MPH
  investigator1_professional_addressKenyatta National Hospital, P.O. Box 12345, Nairobi, Kenya
  investigator1_telephone+254-722-123-456
  investigator1_emailsamuel.mwangi@kenyahospitals.org
  organisations_transferred_No
  number_participants360000
  notification<p>\n N/A</p>\n
  approval_date21-06-2024
  submitted1
  deleted0
  deleted_date(null)
  deactivated0
  date_submitted24-05-2024
  unsubmitted0
  initial_date_submitted(null)
  admin_stopped0
  admin_stopped_reason(null)
  approved2
  approved_reasonApproved
  approved_date(null)
  final_report(null)
  implication_results(null)
  quantity_imported(null)
  quantity_dispensed(null)
  quantity_destroyed(null)
  quantity_exported(null)
  balance_site(null)
  final_date(null)
  ecitizen_invoice301885
  modified2024-06-21 07:00:59
  created2024-05-24 11:44:21
  ai_content(null)
  InvestigatorContact(array)
  0(array)
  id17
  application_id43
  given_nameGrace
  middle_name
  family_nameOmondi
  qualificationPhD
  professional_addressUniversity of Nairobi, P.O. Box 54321, Nairobi, Kenya
  telephone+254-733-987-654
  emailgrace.omondi@uonbi.ac.ke
  investigator_roleprincipal
  created2024-05-24 11:52:46
  modified2024-05-24 12:58:04
  SiteDetail(array)
  0(array)
  id37
  application_id43
  county_id1
  site_nameMombasa General Hospital
  physical_addressMoi Avenue, Mombasa
  contact_details+254-41-222-2222, P.O. Box: 12345-00100
  contact_personDr. Jane Kinyua
  site_capacity(null)
  misc(null)
  created2013-02-21 08:45:41
  modified2024-05-24 12:58:04
  County(array)
  id1
  county_nameMombasa
  created2012-05-31 16:15:11
  modified2012-07-09 13:06:23
  1(array)
  id1663
  application_id43
  county_id42
  site_nameKisumu Medical Center
  physical_addressOginga Odinga Road, Kisumu
  contact_detailsTel: +254-57-333-3333, P.O. Box: 54321-40100
  contact_personDr. Peter Otieno
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id42
  county_nameKisumu
  created2012-06-15 10:27:02
  modified2012-06-15 10:27:02
  2(array)
  id1664
  application_id43
  county_id32
  site_nameNakuru Community Hospital
  physical_addressKenyatta Avenue, Nakuru
  contact_details+254-51-444-4444, P.O. Box: 67890-20100
  contact_personDr. Susan Mwangi
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id32
  county_nameNakuru
  created2012-06-15 10:25:52
  modified2012-06-15 10:25:52
  3(array)
  id1665
  application_id43
  county_id27
  site_name Eldoret Health Center
  physical_addressUganda Road, Eldoret
  contact_detailsTel: +254-53-555-5555, P.O. Box: 98765-30100
  contact_personDr. David Kimani
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id27
  county_nameUasin Gishu
  created2012-06-15 10:25:15
  modified2012-06-15 10:25:15
  4(array)
  id1666
  application_id43
  county_id22
  site_nameThika District Hospital
  physical_address Uhuru Street, Thika
  contact_detailsTel: +254-67-666-6666, P.O. Box: 23456-50100
  contact_personDr. Mercy Wanjiku
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id22
  county_nameKiambu
  created2012-06-15 10:24:37
  modified2012-06-15 10:24:37
  5(array)
  id1667
  application_id43
  county_id26
  site_name Kitale Medical Clinic
  physical_addressHospital Road, Kitale
  contact_detailsTel: +254-54-777-7777, P.O. Box: 34567-30200
  contact_personDr. James Mugo
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id26
  county_nameTrans Nzoia
  created2012-06-15 10:25:05
  modified2012-06-15 10:25:05
  6(array)
  id1668
  application_id43
  county_id16
  site_nameMachakos General Hospital
  physical_addressMwatu Wa Ngoma Road, Machakos
  contact_detailsTel: +254-44-888-8888, P.O. Box: 45678-90100
  contact_personDr. Alice Mutisya
  site_capacity(null)
  misc(null)
  created2024-05-24 12:28:23
  modified2024-05-24 12:58:04
  County(array)
  id16
  county_nameMachakos
  created2012-06-15 10:23:55
  modified2012-06-15 10:23:55
  Sponsor(array)
  0(array)
  id17
  application_id43
  sponsorABC Pharmaceuticals Ltd.
  sponsor_typeIndustry
  contact_personJohn Smith
  address 789 Oak Avenue, Nairobi, Kenya
  telephone_number+254-20-987-6543
  fax_number+254-20-987-6544
  cell_number+254-712-345-678
  email_addressjohn.smith@abcpharma.co.ke
  created2024-05-24 11:52:46
  modified2024-05-24 12:58:04
  PublicAction(array)
  labelApproved
  date21-06-2024
- page_options(array)
  1010
  5050
  100100
- redir
- $request->data(array)
  Application(array)
  statusapproved
- $this->validationErrors(array)
  Permission(empty)
  Aro(empty)
  Aco(empty)
  Application(empty)
  User(empty)
  TrialStatus(empty)
  InvestigatorContact(empty)
  Sponsor(empty)
  SiteDetail(empty)
  County(empty)
- Loaded Helpers(array)
  0Html
  1Form
  2Session
  3Text
  4Number
  5SimpleGraph
  6Paginator
  7DebugTimer
  8Toolbar
  9HtmlToolbar
====

Environment

App Constants

Constant	Value
MEDIA	'/var/www/ctr/app/webroot/media/'
MEDIA_STATIC	'/var/www/ctr/app/webroot/media/static/'
MEDIA_FILTER	'/var/www/ctr/app/webroot/media/filter/'
MEDIA_TRANSFER	'/var/www/ctr/app/webroot/media/transfer/'
MEDIA_URL	'media/'
MEDIA_STATIC_URL	'media/static/'
MEDIA_FILTER_URL	'media/filter/'
MEDIA_TRANSFER_URL	'media/transfer/'
HTTP_HOST	'45.79.161.190:8080'
HTTP_BASE	'http://45.79.161.190:8080'
HTTP_SELF	'/app/webroot/index.php'
HTTP_URI	'/applications/index/sort:study_title/direction:desc/status:approved/page:3'
CHOWN_PUBLIC	(int) 504
LF	''
NL	''
CR	''
TB	''
BR	' '
WINDOWS	false
FORMAT_DB_DATETIME	'Y-m-d H:i:s'
FORMAT_DB_DATE	'Y-m-d'
FORMAT_DB_TIME	'H:i:s'
DEFAULT_DATETIME	'0000-00-00 00:00:00'
DEFAULT_DATE	'0000-00-00'
DEFAULT_TIME	'00:00:00'
FILES	'/var/www/ctr/app/files/'
LOCALE	'/var/www/ctr/app/locale/'
CLASS_USER	'User'
VALID_ALPHA	'/^[a-zA-Z]+$/'
VALID_ALPHA_UNDERSCORES	'/^[a-zA-Z_]+$/'
VALID_ALPHA_MINUS_UNDERSCORES	'/^[a-zA-Z_-]+$/'
VALID_ALPHA_WHITESPACES	'/^[a-zA-Z ]+$/'
VALID_ALPHANUMERIC_UNDERSCORES	'/^[\da-zA-Z_]+$/'
VALID_ALPHANUMERIC_MINUS_UNDERSCORES	'/^[\da-zA-Z_-]+$/'
VALID_ALPHANUMERIC_WHITESPACES	'/^[\da-zA-Z ]+$/'
VALID_ALPHANUMERIC_WHITESPACES_UNDERSCORES	'/^[\da-zA-Z _]+$/'
VALID_NUMERIC_UNDERSCORES	'/^[\d_]+$/'
VALID_NUMERIC_WHITESPACES	'/^[\d ]+$/'
VALID_NUMERIC_WHITESPACES_UNDERSCORES	'/^[\d _]+$/'
VALID_INTEGERS	'/^[\d]+$/'
FORMAT_NICE_YMDHMS	'd.m.Y, H:i:s'
FORMAT_NICE_YMDHM	'd.m.Y, H:i'
FORMAT_NICE_YM	'm.Y'
FORMAT_NICE_YMD	'd.m.Y'
FORMAT_NICE_MD	'd.m.'
FORMAT_NICE_D	'd'
FORMAT_NICE_W_NUM	'w'
FORMAT_NICE_W_ABBR	'D'
FORMAT_NICE_W_FULL	'l'
FORMAT_NICE_M	'm'
FORMAT_NICE_M_ABBR	'M'
FORMAT_NICE_M_FULL	'F'
FORMAT_NICE_Y_ABBR	'y'
FORMAT_NICE_Y	'Y'
FORMAT_NICE_HM	'H:i'
FORMAT_NICE_HMS	'H:i:s'
FORMAT_LOCAL_WA_YMDHMS	'%a, %d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_WF_YMDHMS	'%A, %d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_WA_YMDHM	'%a, %d.%m.%Y, %H:%M'
FORMAT_LOCAL_WF_YMDHM	'%A, %d.%m.%Y, %H:%M'
FORMAT_LOCAL_YMDHMS	'%d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_YMDHM	'%d.%m.%Y, %H:%M'
FORMAT_LOCAL_YMD	'%d.%m.%Y'
FORMAT_LOCAL_MD	'%d.%m.'
FORMAT_LOCAL_D	'%d'
FORMAT_LOCAL_W_NUM	'%w'
FORMAT_LOCAL_W_ABBR	'%a'
FORMAT_LOCAL_W_FULL	'%A'
FORMAT_LOCAL_M	'%m'
FORMAT_LOCAL_M_ABBR	'%b'
FORMAT_LOCAL_M_FULL	'%B'
FORMAT_LOCAL_Y_ABBR	'%y'
FORMAT_LOCAL_YMS_ABBR	'%d.%m.%y'
FORMAT_LOCAL_Y	'%Y'
FORMAT_LOCAL_H	'%H'
FORMAT_LOCAL_S	'%S'
FORMAT_LOCAL_HM	'%H:%M'
FORMAT_LOCAL_HMS	'%H:%M:%S'
CHAR_LESS	'<'
CHAR_GREATER	'>'
CHAR_QUOTE	'"'
CHAR_APOSTROPHE	'''
CHAR_ARROWS	'»'
CHAR_ARROWS_R	'»'
CHAR_ARROWS_L	'«'
CHAR_AVERAGE	'Ø'
CHAR_INFIN	'∞'
CHAR_MILL	'‰'
CHAR_PLUSMN	'±'
CHAR_HELLIP	'…'
CHAR_CIRCA	'≈'
CHAR_CHECKBOX_EMPTY	'☐]'
CHAR_CHECKBOX_MAKRED	'☑'
CHAR_CHECKMARK	'✓'
CHAR_CHECKMARK_BOLD	'✔'
CHAR_BALLOT	'✗'
CHAR_BALLOT_BOLD	'✘'
CHAR_ABOUT	'≈'
CHAR_RPIME	'′'
CHAR_DOUBLE_RPIME	'″'

CakePHP Constants

Constant	Value
APP	'/var/www/ctr/app/'
APP_DIR	'app'
APPLIBS	'/var/www/ctr/app/Lib/'
CACHE	'/var/www/ctr/app/tmp/cache/'
CAKE	'/var/www/ctr/lib/Cake/'
CAKE_CORE_INCLUDE_PATH	'/var/www/ctr/lib'
CORE_PATH	'/var/www/ctr/lib/'
CAKE_VERSION	'2.2.2'
CSS	'/var/www/ctr/app/webroot/css/'
CSS_URL	'css/'
DS	'/'
FULL_BASE_URL	'http://45.79.161.190:8080'
IMAGES	'/var/www/ctr/app/webroot/img/'
IMAGES_URL	'img/'
JS	'/var/www/ctr/app/webroot/js/'
JS_URL	'js/'
LOGS	'/var/www/ctr/app/tmp/logs/'
ROOT	'/var/www/ctr'
TESTS	'/var/www/ctr/app/Test/'
TMP	'/var/www/ctr/app/tmp/'
VENDORS	'/var/www/ctr/vendors/'
WEBROOT_DIR	'webroot'
WWW_ROOT	'/var/www/ctr/app/webroot/'

PHP Environment

Environment Variable	Value
Php Version	'5.6.40-63+ubuntu18.04.1+deb.sury.org+2'
Redirect Redirect Status	'200'
Redirect Status	'200'
Http Accept	'/'
Http User Agent	'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)'
Http Cookie	'CAKEPHP=ve5s2aflo4ibrcnh8v60fomqd0'
Http Accept Encoding	'gzip, br, zstd, deflate'
Http Host	'45.79.161.190:8080'
Http Via	'1.1 squid-proxy-5b96dc6d46-5rn9l (squid/6.13)'
Http X Forwarded For	'10.3.233.74'
Http Cache Control	'max-age=259200'
Http Connection	'keep-alive'
Path	'/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin:/snap/bin'
Server Signature	' Apache/2.4.41 (Ubuntu) Server at 45.79.161.190 Port 8080 '
Server Software	'Apache/2.4.41 (Ubuntu)'
Server Name	'45.79.161.190'
Server Addr	'45.79.161.190'
Server Port	'8080'
Remote Addr	'216.73.216.151'
Document Root	'/var/www/ctr'
Request Scheme	'http'
Context Prefix	''
Context Document Root	'/var/www/ctr'
Server Admin	'webmaster@localhost'
Script Filename	'/var/www/ctr/app/webroot/index.php'
Remote Port	'1408'
Redirect Url	'/app/webroot/applications/index/sort:study_title/direction:desc/status:approved/page:3'
Gateway Interface	'CGI/1.1'
Server Protocol	'HTTP/1.1'
Request Method	'GET'
Query String	''
Request Uri	'/applications/index/sort:study_title/direction:desc/status:approved/page:3'
Script Name	'/app/webroot/index.php'
Php Self	'/app/webroot/index.php'
Request Time Float	(float) 1790921017.551
Request Time	(int) 1790921017

====

Include
+
Included Files

Include Paths
- 0/var/www/ctr/app/Plugin/Media/Lib/mm/src
- 1/var/www/ctr/lib
- 3/usr/share/php
- 4-> /var/www/ctr/lib/Cake/
Included Files
- core(array)
  Behavior(array)
  0CORE/Model/Behavior/TreeBehavior.php
  1CORE/Model/Behavior/ContainableBehavior.php
  2CORE/Model/Behavior/AclBehavior.php
  Cache(array)
  0CORE/Cache/Cache.php
  1CORE/Cache/Engine/FileEngine.php
  2CORE/Cache/CacheEngine.php
  Component(array)
  0CORE/Controller/Component/AclComponent.php
  1CORE/Controller/Component/Acl/DbAcl.php
  2CORE/Controller/Component/Acl/AclInterface.php
  3CORE/Controller/Component/AuthComponent.php
  4CORE/Controller/Component/RequestHandlerComponent.php
  5CORE/Controller/Component/SessionComponent.php
  6CORE/Controller/Component/PaginatorComponent.php
  Config(array)
  0CORE/Config/routes.php
  1CORE/Config/config.php
  Controller(array)
  0CORE/Controller/Controller.php
  1CORE/Controller/ComponentCollection.php
  2CORE/Controller/Component.php
  Datasource(array)
  0CORE/Model/Datasource/CakeSession.php
  1CORE/Model/Datasource/Database/Mysql.php
  2CORE/Model/Datasource/DboSource.php
  3CORE/Model/Datasource/DataSource.php
  Error(array)
  0CORE/Error/exceptions.php
  1CORE/Error/ErrorHandler.php
  I18n(array)
  0CORE/I18n/I18n.php
  1CORE/I18n/L10n.php
  Log(array)
  0CORE/Log/CakeLog.php
  1CORE/Log/LogEngineCollection.php
  2CORE/Log/Engine/FileLog.php
  3CORE/Log/Engine/BaseLog.php
  4CORE/Log/CakeLogInterface.php
  Model(array)
  0CORE/Model/ConnectionManager.php
  1CORE/Model/Permission.php
  2CORE/Model/Model.php
  3CORE/Model/BehaviorCollection.php
  4CORE/Model/Aro.php
  5CORE/Model/AclNode.php
  6CORE/Model/Aco.php
  7CORE/Model/ModelBehavior.php
  Network(array)
  0CORE/Network/CakeRequest.php
  1CORE/Network/CakeResponse.php
  Other(array)
  0CORE/bootstrap.php
  1CORE/basics.php
  2CORE/Core/App.php
  3CORE/Core/Configure.php
  4CORE/Core/CakePlugin.php
  5CORE/Event/CakeEventListener.php
  6CORE/Event/CakeEvent.php
  7CORE/Event/CakeEventManager.php
  8CORE/Core/Object.php
  Routing(array)
  0CORE/Routing/Dispatcher.php
  1CORE/Routing/Filter/AssetDispatcher.php
  2CORE/Routing/DispatcherFilter.php
  3CORE/Routing/Filter/CacheDispatcher.php
  4CORE/Routing/Router.php
  5CORE/Routing/Route/CakeRoute.php
  6CORE/Routing/Route/PluginShortRoute.php
  Utility(array)
  0CORE/Utility/Hash.php
  1CORE/Utility/Inflector.php
  2CORE/Utility/ObjectCollection.php
  3CORE/Utility/Debugger.php
  4CORE/Utility/String.php
  5CORE/Utility/ClassRegistry.php
  6CORE/Utility/Set.php
  7CORE/Utility/Sanitize.php
  View(array)
  0CORE/View/HelperCollection.php
- app(array)
  Behavior(array)
  0APP/Model/Behavior/SoftDeleteBehavior.php
  Config(array)
  0APP/Config/core.php
  1APP/Config/bootstrap.php
  2APP/Config/routes.php
  3APP/Config/database.php
  Controller(array)
  0APP/Controller/ApplicationsController.php
  1APP/Controller/AppController.php
  Model(array)
  0APP/Model/AppModel.php
  1APP/Model/Application.php
  2APP/Model/User.php
  3APP/Model/TrialStatus.php
  4APP/Model/InvestigatorContact.php
  5APP/Model/Sponsor.php
  6APP/Model/SiteDetail.php
  7APP/Model/County.php
  Other(array)
  0APP/webroot/index.php
- plugins(array)
  CakePdf(array)
  Config(array)
  0CakePdf/Config/bootstrap.php
  1CakePdf/Config/routes.php
  CakeResque(array)
  Config(array)
  0CakeResque/Config/bootstrap.php
  Plugin(array)
  0CakeResque/Lib/CakeResque.php
  1CakeResque/vendor/kamisama/php-resque-ex/lib/Resque.php
  2CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Event.php
  3CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Exception.php
  DebugKit(array)
  Component(array)
  0DebugKit/Controller/Component/ToolbarComponent.php
  Plugin(array)
  0DebugKit/Lib/DebugMemory.php
  1DebugKit/Lib/Panel/HistoryPanel.php
  2DebugKit/Lib/DebugPanel.php
  3DebugKit/Lib/Panel/SessionPanel.php
  4DebugKit/Lib/Panel/RequestPanel.php
  5DebugKit/Lib/Panel/SqlLogPanel.php
  6DebugKit/Lib/Panel/TimerPanel.php
  7DebugKit/Lib/Panel/LogPanel.php
  8DebugKit/Lib/Log/Engine/DebugKitLog.php
  9DebugKit/Lib/Panel/VariablesPanel.php
  10DebugKit/Lib/Panel/EnvironmentPanel.php
  11DebugKit/Lib/Panel/IncludePanel.php
  12DebugKit/Lib/DebugTimer.php
  Media(array)
  Config(array)
  0Media/Config/bootstrap.php
  Plugin(array)
  0Media/Lib/mm/src/Mime/Type.php
  1Media/Lib/mm/src/Mime/Type/Magic/Adapter/Fileinfo.php
  2Media/Lib/mm/src/Mime/Type/Magic/Adapter.php
  3Media/Lib/mm/src/Mime/Type/Glob/Adapter/Memory.php
  4Media/Lib/mm/src/Mime/Type/Glob/Adapter.php
  5Media/Lib/mm/src/Media/Process.php
  6Media/Lib/mm/src/Media/Info.php
  Search(array)
  Component(array)
  0Search/Controller/Component/PrgComponent.php
  Behavior(array)
  0Search/Model/Behavior/SearchableBehavior.php
  Shim(array)
  Config(array)
  0Shim/Config/bootstrap.php
  Tools(array)
  Config(array)
  0Tools/Config/bootstrap.php
====

Clinical Trial Applications - Approved: Filter, Search, and view applications {lang: 'en-GB'}

Request History

Session

Request

Cake Params

Post data

Query string

Cookie

Current Route

Sql Logs

default

Total Time: 9 ms Total Queries: 20 queries

Query Explain:

Memory

Timers

Logs

View Variables

App Constants

CakePHP Constants

PHP Environment

Included Files

Include Paths

Included Files

Clinical Trial Applications - Approved: Filter, Search, and view applications

Total Time: 9 ms
Total Queries: 20 queries